Drug Trial Radar · NCT03861793
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Feb 26, 2019
Primary completion
Mar 1, 2023
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- Mural Oncology, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Conditions
- Advanced Solid Tumors
Interventions
ALKS 4230Biological
SC injection administered in the back of the arm or the abdomen
PembrolizumabBiological
Administered as an intravenous (IV) infusion over 30 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part ATime frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months
- Number of subjects experiencing AEs that are both serious and drug-related in Part BTime frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months
- Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type.Time frame: From time of therapy until the date of first documented tumor progression, assessed up to 24 months
Locations
48 sites in 6 countries. Site status is shown where the registry gives one.
Mural Oncology Investigational Site
Los Angeles, California
Mural Oncology Investigational Site
Los Angeles, California
Mural Oncology Investigational Site
Washington D.C., District of Columbia
Mural Oncology Investigational Site
Atlanta, Georgia
Mural Oncology Investigational Site
Chicago, Illinois
Mural Oncology Investigational Site
Bethesda, Maryland
Mural Oncology Investigational Site
Detroit, Michigan
Mural Oncology Investigational Site
Saint Paul, Minnesota
Mural Oncology Investigational Site
Morristown, New Jersey
Mural Oncology Investigational Site
Buffalo, New York
Mural Oncology Investigational Site
Huntersville, North Carolina
Mural Oncology Investigational Site
Cincinnati, Ohio
Mural Oncology Investigational Site
Philadelphia, Pennsylvania
Mural Oncology Investigational Site
Charleston, South Carolina
Mural Oncology Investigational Site
Houston, Texas
Mural Oncology Investigational Site
Salt Lake City, Utah
Mural Oncology Investigational Site
Milwaukee, Wisconsin
Mural Oncology Investigational Site
Edmonton, Alberta, Canada
Mural Oncology Investigational Site
Hamilton, Ontario, Canada
Mural Oncology Investigational Sites
Montreal, Quebec, Canada
Mural Oncology Investigational Site
Montreal, Quebec, Canada
Mural Oncology Investigational Site
Montreal, Quebec, Canada
Mural Oncology Investigational Site
Québec, Quebec, Canada
Mural Oncology Investigational Site
Rotterdam, Netherlands
Mural Oncology Investigational Site
Utrecht, Netherlands
National Cancer Center
Goyang, South Korea
Inha University Hospital
Incheon, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University Health System - Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea St. Vincent's Hospital
Suwon, South Korea
Mural Oncology Investigational Site
Badalona, Spain
Mural Oncology Investigational Site
Córdoba, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Mural Oncology Investigational Site
Madrid, Spain
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.